Patents Examined by Christian C Boesen
-
Patent number: 11970787Abstract: The present disclosure provides methods, compositions, kits, and systems useful in the determination and evaluation of the immune repertoire. In one aspect, target-specific primer panels provide for the effective amplification of sequences of T cell receptor and/or B cell receptor chains with improved sequencing accuracy and resolution over the repertoire. Variable regions associated with the immune cell receptor are resolved to effectively portray clonal diversity of a biological sample and/or differences associated with the immune cell repertoire of a biological sample.Type: GrantFiled: February 4, 2021Date of Patent: April 30, 2024Assignee: Life Technologies CorporationInventors: Timothy Looney, Geoffrey Lowman, Lifeng Lin
-
Patent number: 11946163Abstract: The invention describes a novel system for identifying optimized gRNAs for use in CRISPR/Cas9 genome editing platforms. The invention allows for the determination of specific gene alterations rendered by a particular gRNA, thereby permitting the generation of optimized gRNA libraries.Type: GrantFiled: June 24, 2021Date of Patent: April 2, 2024Assignee: KSQ Therapeutics, Inc.Inventors: Gregory V. Kryukov, Michael R. Schlabach, Jason J. Merkin
-
Patent number: 11946162Abstract: The invention relates to methods and products for generating diverse libraries of genetic material. The products include libraries and constructed nucleic acids as well as kits and databases and systems thereof.Type: GrantFiled: March 17, 2021Date of Patent: April 2, 2024Assignee: Massachusetts Institute of TechnologyInventors: Dehua Zhao, Christopher A. Voigt, Michael Joseph Smanski
-
Patent number: 11932697Abstract: The present invention relates to a polypeptide comprising an antigen binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen binding activity of the antigen binding domain, and having a longer half-life than that of the antigen binding domain existing alone, methods for producing and screening for the polypeptide, a pharmaceutical composition comprising the polypeptide, methods for producing and screening for a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH, and a fusion polypeptide library including a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH.Type: GrantFiled: September 17, 2021Date of Patent: March 19, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hiroyuki Ishikawa, Naoka Hironiwa
-
Patent number: 11926926Abstract: Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.Type: GrantFiled: June 9, 2020Date of Patent: March 12, 2024Assignee: Takeda Pharmaceutical Company LimitedInventor: Robert Charles Ladner
-
Patent number: 11920258Abstract: Antibody libraries comprising a plurality of heavy chain variable domains and/or a plurality of light chain variable domains, which comprise complementary determining regions (CDRs) found in naturally-occurring human antibodies, and methods of making such antibody libraries. The antibody libraries are free of members that comprise one or more liabilities affecting one or more features of such members. Further, the antibody libraries comprise members having heavy chain and/or light chain CDRs not found in the same naturally-occurring human antibody.Type: GrantFiled: January 29, 2021Date of Patent: March 5, 2024Assignee: RULES-BASED MEDICINE INC.Inventors: Andrew Raymon Morton Bradbury, Michael Frank Erasmus, Andre Teixeira
-
Patent number: 11912987Abstract: This invention describes a novel CRISPR/Cas9 target identification platform permitting the discovery of novel genes and pathways involved in the ability of T cells and NK cells to react against and generate an anti-tumor response.Type: GrantFiled: June 24, 2021Date of Patent: February 27, 2024Assignee: KSQ Therapeutics, Inc.Inventor: Micah Benson
-
Patent number: 11913137Abstract: This application provides an improved screening method for the selection of target-binding proteins having desirable biophysical properties. The method combines mRNA display and yeast surface display in a way that takes advantage of the desirable attributes of both processes.Type: GrantFiled: June 8, 2021Date of Patent: February 27, 2024Assignee: Bristol-Myers Squibb CompanyInventor: Dasa Lipovsek
-
Patent number: 11912778Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.Type: GrantFiled: August 15, 2022Date of Patent: February 27, 2024Assignee: Denali Therapeutics Inc.Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
-
Patent number: 11912765Abstract: The present invention relates to certain new methods to select epitopes for antibodies. The present invention also provides a method of generating an antibody (e.g. a functional antibody) to a protein, said method comprising (i) identifying an antigenic epitope in said protein by exposing the protein to limited or restricted proteolysis by contacting the protein with at least one protease to form at least one digested, deconstructed or truncated version of the protein and at least one surface-exposed peptide that is cleaved off from the protein by the action of said protease and generating an antigenic epitope based on said surface-exposed peptide; and (ii) raising an antibody against the antigenic epitope. The present invention also provides antigenic epitopes and antibodies against such epitopes.Type: GrantFiled: September 29, 2021Date of Patent: February 27, 2024Assignee: OBLIQUE THERAPEUTICS ABInventors: Owe Orwar, Carolina Trkulja
-
Patent number: 11912989Abstract: An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries.Type: GrantFiled: February 23, 2021Date of Patent: February 27, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shigero Tamba, Shun Shimizu, Kanako Tatsumi, Shojiro Kadono, Hiroki Kawauchi, Kazuhiro Ohara, Masayuki Matsushita, Takashi Emura, Masaki Kamimura
-
Patent number: 11913138Abstract: Methods for screening of affinity reagents for many target proteins of interest simultaneously. Arrayed targets (e.g., peptide, protein, RNA, cell, etc.) are used in affinity selection experiments to reduce the amount of target needed and to improve the throughput of discovering recombinant affinity reagents to a large collection of targets.Type: GrantFiled: August 18, 2021Date of Patent: February 27, 2024Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Joshua Labaer, Kevin Gorman, Brian Kay, Jie Wang, Ji Qiu
-
Patent number: 11912756Abstract: Compositions, methods and uses of high-diversity nucleic acid library that encodes a plurality of antibodies or antibody fragments are presented. The high-diversity nucleic acid library comprises or is derived from (1) a VH-CDR1/2 sub-library, (2) a plurality of VH-CDR3 sub-libraries, and (3) a VL sub-library, each of which comprises a plurality of members. Preferably, each member of the sub-libraries comprises at least one random cassette that has a plurality of degenerate base positions. In an especially preferred embodiment, at least portions of at least two members of the VH-CDR1/2 sub-library, the plurality of VH-CDR3 sub-libraries, and the VL sub-library are recombined to form an expression library member in an expression library, where each member of the expression library encodes a distinct antibody or antibody fragment.Type: GrantFiled: April 21, 2021Date of Patent: February 27, 2024Assignee: NantBio, Inc.Inventor: Clifford Anders Olson
-
Patent number: 11905623Abstract: Some aspects of the present disclosure provide methods for evolving recombinases to recognize target sequences that differ from the canonical recognition sequences. Some aspects of this disclosure provide evolved recombinases, e.g., recombinases that bind and recombine naturally-occurring target sequences, such as, e.g., target sequences within the human Rosa26 locus. Methods for using such recombinases for genetically engineering nucleic acid molecules in vitro and in vivo are also provided. Some aspects of this disclosure also provide libraries and screening methods for assessing the target site preferences of recombinases, as well as methods for selecting recombinases that bind and recombine a non-canonical target sequence with high specificity.Type: GrantFiled: August 10, 2021Date of Patent: February 20, 2024Assignee: President and Fellows of Harvard CollegeInventors: David R. Liu, David B. Thompson, Jeffrey L. Bessen
-
Patent number: 11866484Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.Type: GrantFiled: March 3, 2021Date of Patent: January 9, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT CURIE, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
-
Patent number: 11834757Abstract: The present specification provides libraries of HLA homozygous induced pluripotent cell lines.Type: GrantFiled: December 5, 2018Date of Patent: December 5, 2023Assignee: New York Blood Center, Inc.Inventors: Pablo Rubinstein, Christopher D. Hillyer
-
Patent number: 11821111Abstract: Methods to create barcoded influenza viruses without disrupting the function of the viral proteins and the proper packaging of the viral genome segments are described. The barcoded influenza viruses can be used within deep mutational scanning libraries to map influenza resistance mutations to therapeutic treatments. The libraries can also be used to predict influenza strains that may become resistant to therapeutic treatments and/or more easily evolve to infect new species. The libraries include features that allow efficient collection and assessment of informative data, obviating bottlenecks of previous approaches.Type: GrantFiled: November 13, 2020Date of Patent: November 21, 2023Assignee: Fred Hutchinson Cancer CenterInventors: Jesse Bloom, Allison Greaney, Andrea Loes, Adam S. Dingens
-
Patent number: 11820810Abstract: The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells, such as transgenic mice or rats or transgenic mouse or rat cells. Furthermore, the invention relates to methods of using the vertebrates to isolate antibodies or nucleotide sequences encoding antibodies. Antibodies, heavy chains, polypeptides, nucleotide sequences, pharmaceutical compositions and uses are also provided by the invention.Type: GrantFiled: May 28, 2020Date of Patent: November 21, 2023Assignee: Kymab LimitedInventors: Allan Bradley, Glenn Friedrich, E-Chiang Lee, Mark Strivens, Nicholas England
-
Patent number: 11821110Abstract: Provided herein are methods of detecting an antibody directed against a pathogen and uses thereof.Type: GrantFiled: July 8, 2020Date of Patent: November 21, 2023Assignees: The Brigham and Women's Hospital, Inc., President and Fellows of Harvard CollegeInventors: Stephen J. Elledge, Harry B. Larman, Tomasz Kula, George Xu
-
Patent number: 11814750Abstract: Provided herein are compositions, methods, and systems for sample processing and/or data analysis. Sample processing may include nucleic acid sample processing and subsequent sequencing. Methods and systems of the present disclosure can be used, for example, for the analysis of a nucleic acid sample from a human, non-human, and combinations thereof.Type: GrantFiled: November 20, 2020Date of Patent: November 14, 2023Assignee: Personalis, Inc.Inventors: John West, Richard Chen, Christian Haudenschild, Gabor Bartha, Shujun Luo